Furthermore, a number of in vitro and in vivo prostate cancer models, including LNCaP cell lines expressing wild-type or mutated AR, have shown that radiation therapy upregulates AR signaling in CRPC, leading to radioresistance [22]. Here, AR is linked to prostate carcinoma.